Study Points

Back to Course Home
Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.

Which of the following is a risk factor for the development of a substance use disorder?
- Genetic predisposition
- Adverse childhood experiences
- Children with conduct problems
- All of the above
No support text associated with this question.Click to Review
All of the following are diagnostic criteria for substance use disorders, EXCEPT:
- Tolerance
- Withdrawal
- Recreational use
- Persistent desire or unsuccessful efforts to cut down or control use
No support text associated with this question.Click to Review
Which of the following statements regarding contingency management interventions is TRUE?
- There is little evidence that substance use is sensitive to the application of contingencies.
- Contrived contingencies are less likely to result in relapse to drug use following removal of the reinforcer.
- Naturalistic contingencies are less likely to maintain the initial gains made by the patient and to facilitate the sustained change of behavior over time.
- The goal is to increase the opportunity cost of substance use by arranging an environment where drug use results in the forfeiture of a predetermined item or privilege.
No support text associated with this question.Click to Review
Which of the following is NOT a primary area addressed by coping and social skill training (CSST)?
- Solitude training
- Cognitive and affective regulation
- Coping skills to manage stressful life events
- Coping skills when substances or substance-related cues are encountered
No support text associated with this question.Click to Review
Which of the following is a common side effect associated with naltrexone?
- Dizziness
- Weight gain
- Difficulty breathing
- Decreased interest in sex
No support text associated with this question.Click to Review
For the treatment of alcohol use disorder, the oral dosage of acamprosate is
- one 333-mg delayed-release tablet twice daily.
- three 50-mg immediate-release tablets twice daily.
- two 333-mg delayed-release tablets three times daily.
- two 100-mg delayed-release tablets three times daily.
No support text associated with this question.Click to Review
Which of the following drugs is considered the criterion standard in reversing respiratory depression and coma in acute opioid overdose?
- LAAM
- Naloxone
- Methadone
- Buprenorphine
No support text associated with this question.Click to Review
The opioid agonist most frequently used in opioid withdrawal is
- LAAM.
- naloxone.
- methadone.
- buprenorphine.
No support text associated with this question.Click to Review
Studies have shown one-year treatment retention rates in methadone programs of
- 25%.
- 50%.
- 80%.
- 100%.
No support text associated with this question.Click to Review
Methadone maintenance is initiated at a dose of
- 5–10 mg.
- 10–30 mg.
- 60–120 mg.
- 120–240 mg.
No support text associated with this question.Click to Review
Compared with methadone, buprenorphine has a
- lower risk of overdose.
- shorter duration of action.
- more severe withdrawal syndrome following cessation.
- All of the above
No support text associated with this question.Click to Review
Buprenorphine is most effective at a dose of
- 2 mg.
- 5 mg.
- 10 mg.
- 12 mg or greater.
No support text associated with this question.Click to Review
Duration of treatment with varenicline tartrate is
- 4 weeks.
- 8 weeks.
- 12 weeks.
- 24 weeks.
No support text associated with this question.Click to Review
Which of the following treatment approaches is recommended by SAMHSA for the management of patients with comorbid opioid and alcohol dependence?
- FDA-approved pharmacotherapy and counseling
- Contingency management together with FDA-approved pharmacotherapy and counseling
- Twelve-step facilitation therapy together with FDA-approved pharmacotherapy and counseling
- None of the above
No support text associated with this question.Click to Review
Which of the following statements regarding comorbid mental and substance use disorders is FALSE?
- In the United States, 1 million adults have cooccurring mental and substance use disorders.
- No specific combinations of mental and substance use disorders are defined uniquely as co occurring disorders.
- Patients with comorbid disorders demonstrate poorer treatment adherence and higher rates of treatment dropout than those without mental illness.
- Integrated treatment for comorbid drug use disorder and mental illness has been found to be consistently superior compared with separate treatment of each diagnosis.
No support text associated with this question.Click to Review
Treatment of comorbid mental and substance use disorders should initially focus on
- stabilization of the patient's substance use disorder.
- stabilization of the patient's mental health disorder.
- a goal of six to nine weeks abstinence before addressing comorbidities.
- any mental disorder symptoms that appear to resolve during abstinence.
No support text associated with this question.Click to Review
Which of the following ethical issue should be considered when caring for patients with substance use disorders?
- Confidentiality
- Access to services
- Informed consent
- All of the above
No support text associated with this question.Click to Review
When opioids are used for acute pain, clinicians should prescribe
- the highest safe dose.
- extended-release opioids.
- a quantity no greater than that needed for the expected duration of severe pain.
- All of the above
No support text associated with this question.Click to Review
In a survey of oncologists regarding end-of-life pain management, what were two of the most important barriers to effective pain relief?
- Patient reluctance to take opioids or to report pain
- Clinician reluctance to prescribe opioids or believe pain reports
- Desire to be a "good" patient and concern about the high cost of medications
- Anxiety about disease progression and unpleasant side effects from pain medications
No support text associated with this question.Click to Review
A patient prescribed opioids for chronic pain who is 65 years of age and displays high levels of pain acceptance and active coping strategies is considered at what level of risk for developing problematic opioid behavioral responses?
- Low
- Medium
- High
- Severe
No support text associated with this question.Click to Review
The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R)
- consists of 5 items.
- is patient administered.
- diagnoses depression in the past month.
- assesses the likelihood of current substance abuse.
No support text associated with this question.Click to Review
Certain questions are useful in screening to determine presence of substance use disorder. One such set of questions is known as the CAGE questionnaire. The CAGE acronym stands for
- Confusion, Agitation, S3 Gallop, Edema.
- Cut down, Annoyed, Guilty, Eye-opener.
- Chloral hydrate, Alcohol, Glutethimide, Ethchlorvynol.
- un-Controllable urge to drink, un-Able to limit intake, un-Grateful for help to stop drinking, un-Excited about treatment.
No support text associated with this question.Click to Review
Which of the following statements regarding pain management in patients with comorbid opioid use disorder is TRUE?
- Identification of an opioid use disorder does not alter the expected benefits and risks of opioid therapy for pain.
- Patients with co-occurring pain and substance use disorder should not receive pain management until their substance use disorder is controlled.
- Clinicians should use nonpharmacologic and nonopioid pharmacologic pain treatments as appropriate to provide optimal pain management for these patients.
- For patients who are treated with buprenorphine for opioid use disorder and experience acute pain, clinicians should not increase the buprenorphine dosing frequency.
No support text associated with this question.Click to Review
Which of the following is NOT one of the 5 A's of monitoring chronic opioid response?
- Analgesia
- Acceptance
- Affect (i.e., patient mood)
- Aberrant drug-related behaviors
No support text associated with this question.Click to Review
For patients considered at medium risk for misuse of prescription opioids, urine drug testing should be completed every
- 6 to 12 weeks.
- 3 to 6 months.
- 6 to 12 months.
- 1 to 2 years.
No support text associated with this question.Click to Review
All of the following statements regarding the Concurrent Use of benzodiazepines in patients prescribed opioids is true, EXCEPT:
- Opioids have the potential for drug dependence and addiction, but benzodiazepines do not.
- If a benzodiazepine is to be discontinued, the clinician should taper the medication gradually.
- In 2019, 16% of persons who died of an opioid overdose also tested positive for benzodiazepines.
- Combining benzodiazepines with opioids is unsafe because both classes of drug cause central nervous system depression and sedation and can decrease respiratory drive.
No support text associated with this question.Click to Review
Which of the following statements regarding the disposal of opioids is TRUE?
- Patients are almost always advised of what to do with unused or expired medications.
- There are no universal recommendations for the proper disposal of unused opioids.
- According to the FDA, most medications should be flushed down the toilet instead of thrown in the trash.
- All of the above
No support text associated with this question.Click to Review
The most common source of nonmedical use of prescribed opioids is from
- a friend or relative for free.
- a prescription from one doctor.
- purchase from a drug dealer or other stranger.
- theft from a doctor's office, clinic, hospital, or pharmacy.
No support text associated with this question.Click to Review
Which of the following behaviors is the most suggestive of an emerging opioid use disorder?
- Asking for specific medications
- Injecting medications meant for oral use
- Reluctance to decrease opioid dosing once stable
- Stockpiling medications during times when pain is less severe
No support text associated with this question.Click to Review
Which government agency is responsible for formulating federal standards for the handling of controlled substances?
- Institutes of Medicine
- U.S. Drug Enforcement Administration
- Office of National Drug Control Policy
- U.S. Department of Health and Human Services
No support text associated with this question.Click to Review

Back to Course Home
Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.

Complete Your CE

Substance Use Disorders and Pain Management: MATE Act Training

Study Points

Which of the following is a risk factor for the development of a substance use disorder?

All of the following are diagnostic criteria for substance use disorders, EXCEPT:

Which of the following statements regarding contingency management interventions is TRUE?

Which of the following is NOT a primary area addressed by coping and social skill training (CSST)?

Which of the following is a common side effect associated with naltrexone?

For the treatment of alcohol use disorder, the oral dosage of acamprosate is

Which of the following drugs is considered the criterion standard in reversing respiratory depression and coma in acute opioid overdose?

The opioid agonist most frequently used in opioid withdrawal is

Studies have shown one-year treatment retention rates in methadone programs of

Methadone maintenance is initiated at a dose of

Compared with methadone, buprenorphine has a

Buprenorphine is most effective at a dose of

Duration of treatment with varenicline tartrate is

Which of the following treatment approaches is recommended by SAMHSA for the management of patients with comorbid opioid and alcohol dependence?

Which of the following statements regarding comorbid mental and substance use disorders is FALSE?

Treatment of comorbid mental and substance use disorders should initially focus on

Which of the following ethical issue should be considered when caring for patients with substance use disorders?

When opioids are used for acute pain, clinicians should prescribe

In a survey of oncologists regarding end-of-life pain management, what were two of the most important barriers to effective pain relief?

A patient prescribed opioids for chronic pain who is 65 years of age and displays high levels of pain acceptance and active coping strategies is considered at what level of risk for developing problematic opioid behavioral responses?

The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R)

Certain questions are useful in screening to determine presence of substance use disorder. One such set of questions is known as the CAGE questionnaire. The CAGE acronym stands for

Which of the following statements regarding pain management in patients with comorbid opioid use disorder is TRUE?

Which of the following is NOT one of the 5 A's of monitoring chronic opioid response?

For patients considered at medium risk for misuse of prescription opioids, urine drug testing should be completed every

All of the following statements regarding the Concurrent Use of benzodiazepines in patients prescribed opioids is true, EXCEPT:

Which of the following statements regarding the disposal of opioids is TRUE?

The most common source of nonmedical use of prescribed opioids is from

Which of the following behaviors is the most suggestive of an emerging opioid use disorder?

Which government agency is responsible for formulating federal standards for the handling of controlled substances?